Omeprazole vs. Lansoprazole: Effectiveness in gastroesophageal reflux disease patients at a Jambi Referral Hospital

Abstract

Background: Omeprazole and lansoprazole, both proton pump inhibitors (PPIs), are widely used to manage gastroesophageal reflux disease (GERD) with comparable outcomes. However, lansoprazole may provide faster symptom relief. This study aimed to compare the clinical effectiveness of omeprazole and lansoprazole in GERD patients.

Method: This observational retrospective cohort study included hospitalized GERD patients at Raden Mattaher Regional Hospital, Jambi, from 2022 to 2024. A total of 117 patients were selected using consecutive sampling. Data were obtained from medical records and analyzed using SPSS version 25.

Results: Most patients were aged 40-59 years (42.7%), female (55.6%), unemployed (55.8%), high school (51.7%), National Health Insurance (93.2%), non-erosive GERD (91.1%), no comorbidities (56.4%), normal BMI (84.2%), average vital signs included blood pressure (130.0 mmHg), pulse (88.0 x/minute), respiration rate (20.0 x/minute), body temperature (36.4°C). The clinical outcome showed negative endoscopic findings (91.1%), length of stay ≤7 days (80.3%) median 5 days. There were no statistically significant differences in clinical improvement between omeprazole and lansoprazole nor type of drug, length of stay, age, gender, grade, occupation or comorbidities (p > 0.05).

Conclusions: The analysis showed no statistically significant difference in clinical outcomes between omeprazole and lansoprazole, indicating comparable effectiveness of both proton pump inhibitors in the improvement of GERD symptoms.